Antibody constructs for CLDN18.2 and CD3

US11692031B2 · kind B2 · utility

Assignees

• AMGEN RESEARCH (MUNICH) GMBH · DE
• AMGEN INC. · US

Inventors

• Christoph Dahlhoff · Munich, DE
• Claudia Blümel · Munich, DE
• Johannes Brozy · Munich, DE
• Tobias Raum · Munich, DE
• Elisabeth Nahrwold · Munich, DE
• Tara Arvedson · Thousand Oaks, US
• Irwin Chen · Moreno Valley, US
• Sandra Ross · Forest Park, US
• Julie Bailis · Los Gatos, US

Key dates

• Filing date: Aug 2, 2019
• Grant date: Jul 4, 2023
• Expiry date: Sep 10, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.